C-erbB-2/neu protein expression, DNA ploidy and S phase in breast cancer

Cell Proliferation

Volumn 29, Issue 7, 1996, Pages 403-412

  Dittadi, R ^a,c   Calderazzo, F ^b   Cabrelle, A ^b   Di Fresco, S ^a   Gion, M ^a   Chieco Bianchi, L ^b  

^a GENERAL HOSPITAL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Ospedale Civile   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; NEU DIFFERENTIATION FACTOR;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BREAST CANCER; CELL CYCLE S PHASE; DNA CONTENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PLOIDY; PROTEIN EXPRESSION;

EID: 0029950468     PISSN: 09607722     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2184.1996.tb00983.x     Document Type: Article

References (30)

1. BAAK JP, CHIN D, VAN DIEST PJ, ORTI ZR, MATZE COK P, BACUS SS. (1991) Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy and morphometric and clinical features in paraffin-embedded invasive breast cancer. Lab. Invest. 64, 215.
2. BACUS SS, BACUS JW, SLAMON DJ, PRESS MF. (1990) Her/2 neu oncogene expression and DNA ploidy analysis in breast cancer. Arch. Pathol. Lab. Med. 114, 164.
3. BEERMAN H, KLUIN PM, HERMANS J, VAN DE VELDE CJH, CORNELISSE CJ. (1990) Prognostic significance of DNA-ploidy in a series of 690 primary breast cancer patients. Int. J. Cancer 45, 34.
4. BORG A, BALDETORP B, FERNO M, KILLANDER D, OLSSON H, SIGURDSSON H. (1991) ErbB-2 amplification in breast cancer with a high rate of proliferation. Oncogene 6, 137.
5. BRADFORD M. (1976) A rapid sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal. Biochem. 72, 248.
6. CHRISTOV K, MILEV A, TODOROV V. (1989) DNA aneuploidy and cell proliferation in breast tumours. Cancer 64, 673.
7. CORNELISSE CJ, VAN DE VELDE CJH, CASPERS RJC, MOOLENAR AJ, HERMANS, J. (1987) DNA ploidy and survival in breast cancer patients. Cytometry 8, 225.
8. DITTADI R, DONISI PM, BRAZZALE A, MARCONATO A, SPINA M, GION M. (1992) Immunoenzymatic assay of erbB2 protein in cancer and non-malignant breast tissue. Relationships with clinical and biochemical parameters. Anticancer Res. 12, 2005.
9. ncu quantitation in breast cancer specimens. Anticancer Res. 13, 1821.
10. DRESSLER LG, SEAMER LC, OWENS MA, CLARK GM, MCGUIRE WL. (1988) DNA flow-cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61, 420.
11. FOEKENS JA, PETERS HA, PORTENGEN H, NOORDERGRAAF E, BERNS PMJJ, KLIJN JGM. (1991) Cell biological prognostic factors in breast cancer: a review. J Clin. Immunoassay 14, 184.
12. GASPARINI G, GULLICK WJ, BEVILACQUA P et al. (1992) Human breast cancer: prognostic significance of the c-erbB-2/neu oncoprotein compared with epidermal growth-factor receptor, DNA ploidy and conventional pathologic features. J. Clin. Oncol. 10, 686.
13. HEDLEY DW, RUGG CA, GELBER RD. (1987) Association of DNA Index and S-phase-fraction with prognosis of nodes positive early breast cancer. Cancer Res. 47, 4729.
14. HYNES NE. (1993) Amplification and overexpression of the erbB-2 gene in human tumours: its involvement in tumour development, significance as a prognostic factor and potential as a target for cancer therapy. Sem. Cancer Biol. 4, 19.
15. KALLIONIEMI OP, HIETANEN T, MATTILA J, LEHTINEN M, LAUSLAHTI K, KOIVULA T. (1987) Aneuploid DNA content and S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. Eur. J. Cancer Clin. Oncol. 23, 277.
16. KALLIONIEMI OP, BLANCO G, ALAVAIKKO M et al. (1988) Improving the prognostic valour of DNA flow-cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer. Cancer 62, 2183.
17. LEE AK, WILEY B, LODA M et al. (1992) DNA ploidy, proliferation, and neu oncogene protein overexpression in breast carcinoma. Mod. Pathol. 5, 61.
18. LEWIS WE. (1990) Prognostic significance of flow cytometric DNA analysis in node-negative breast cancer patients. Cancer 65, 2315.
19. MOLINA R, CIOCCA DR, TANDON AK et al. (1992) Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques. Anticancer Res. 12, 1965.
20. O'REILLY SM, CAMPLEJOHN RS, BARNES DM et al. (1990) DNA-Index, S-phase fraction, histological grade and prognosis in breast cancer. Br. J. Cancer 61, 671.
21. O'REILLY SM, BARNES DM, CAMPLEJOHN RS, BARTKOVA J, GREGORY WM, RICHARDS MA. (1991) The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br. J. Cancer 63, 444.
22. PERREN TJ. (1991) c-erbB-2 oncogene a prognostic marker in breast cancer. Br. J. Cancer 63, 328.
23. PIFFANELLI A, DITTADI R, CATOZZI L et al. (1996) Determination of erbB2 protein in breast cancer tissue by different methods. Relationships with other biological parameters. Br. Cancer Res. Treat. 37, 267.
24. POLLER DN, GALEA M, PEARSON D et al. (1991) Nuclear and flow-cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma. Breast Cancer Res. Treat. 20, 3.
25. SLAMON DJ, CLARK GM, WONG SG, LEVIN WJ, ULRICH A, MCGUIRE WL. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177.
26. STAL O, SULLIVAN S, SUN XF, WINGREN S, NORDENSKJOLD B. (1994) Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometer. Cytometry 16, 160.
27. SUNDERLAND MC, MCGUIRE WL. (1990) Prognostic indicators in invasive breast cancer. Surg. Clin. North Am. 70, 989.
28. TOIKKANEN S, JOENSUU H, KLEMI P. (1989) The prognostic significance of nuclear DNA content in invasive breast cancer - a study with long-term follow-up. Br J. Cancer 60, 693.
29. TOMMASI S, PARADISO A, MANGIA A et al. (1991) Biological correlation between HER-2/neu and proliferative activity in human breast cancer. Anticancer Res. 11, 1395.
30. WITZIG TE, GONHOROF NJ, THENEAU T et al. (1991) DNA content flow-cytometry as a prognostic factor for node-positive breast cancer. Cancer 68, 1781.